(Q46419792)
Statements
Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy (English)
Susumu Ogawa
Takefumi Mori
Kazuhiro Nako